Biotech Values

[tinkershaw]

<<<What is their reasoning for misrepresenting the status of Lovenox?>>>

To keep their share price up. If Teva can get generic lovenox approved, then there really is nothing special about what MNTA did, now is there? If Teva cannot get generic lovenox approved, then dang, perhaps MNTA really does have superlative and unique technology that can just as easily take apart copaxone (counter to Teva's fervant hollering to the contrary).

The longer they can keep the share price up from copaxone FUD, the better it is for Teva. Generic lovenox itself is material, but nothing stupendous to Teva in the long-run, but MNTA's abilityt to recreate copaxone is earth shaking to Teva. The longer they can maintain the fiction that MNTA has done nothing special, the better it is for the share price for investor's being told left and right by analysts and Teva that the copaxone threat is no biggy.

Thats my initial thought on it.

Tinker